Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 273

1.

Central pre-proglucagon derived peptides: opportunities for treatment of obesity.

Larsen PJ, Vrang N, Tang-Christensen M.

Curr Pharm Des. 2003;9(17):1373-82. Review.

PMID:
12769729
2.

Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.

Baggio LL, Huang Q, Brown TJ, Drucker DJ.

Gastroenterology. 2004 Aug;127(2):546-58.

PMID:
15300587
3.

Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like Peptide-1.

Cani PD, Neyrinck AM, Maton N, Delzenne NM.

Obes Res. 2005 Jun;13(6):1000-7.

4.

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.

Holst JJ.

Expert Opin Emerg Drugs. 2004 May;9(1):155-66. Review.

PMID:
15155141
5.

Ups and downs for neuropeptides in body weight homeostasis: pharmacological potential of cocaine amphetamine regulated transcript and pre-proglucagon-derived peptides.

Larsen PJ, Vrang N, Tang-Christensen M, Jensen PB, Hay-Schmidt A, Rømer J, Bjerre-Knudsen L, Kristensen P.

Eur J Pharmacol. 2002 Apr 12;440(2-3):159-72. Review.

PMID:
12007533
6.

Glucagon-like peptide containing pathways in the regulation of feeding behaviour.

Tang-Christensen M, Vrang N, Larsen PJ.

Int J Obes Relat Metab Disord. 2001 Dec;25 Suppl 5:S42-7.

PMID:
11840214
7.

Glucagon-like peptides.

Drucker DJ.

Diabetes. 1998 Feb;47(2):159-69. Review.

PMID:
9519708
8.

Enteroglucagon.

Holst JJ.

Annu Rev Physiol. 1997;59:257-71. Review.

PMID:
9074764
9.

The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice.

Maida A, Lovshin JA, Baggio LL, Drucker DJ.

Endocrinology. 2008 Nov;149(11):5670-8. doi: 10.1210/en.2008-0336. Epub 2008 Jul 31.

PMID:
18669601
10.

Gut hormones as peripheral anti obesity targets.

Small CJ, Bloom SR.

Curr Drug Targets CNS Neurol Disord. 2004 Oct;3(5):379-88. Review.

PMID:
15544446
12.

Biologic actions and therapeutic potential of the proglucagon-derived peptides.

Drucker DJ.

Nat Clin Pract Endocrinol Metab. 2005 Nov;1(1):22-31. Review.

PMID:
16929363
13.

[Glucagon-like peptides--synthesis, biological actions and some clinical implications].

Otto Buczkowska E, Dworzecki T.

Przegl Lek. 2004;61(9):947-50. Review. Polish.

PMID:
15803906
14.

Glucagon and glucagon-like peptide receptors as drug targets.

Estall JL, Drucker DJ.

Curr Pharm Des. 2006;12(14):1731-50. Review.

PMID:
16712485
15.

Proglucagon-derived peptides: mechanisms of action and therapeutic potential.

Sinclair EM, Drucker DJ.

Physiology (Bethesda). 2005 Oct;20:357-65. Review.

16.

The mechanism of action for oxyntomodulin in the regulation of obesity.

Wynne K, Field BC, Bloom SR.

Curr Opin Investig Drugs. 2010 Oct;11(10):1151-7. Review.

PMID:
20872318
17.

Peripheral oxyntomodulin reduces food intake and body weight gain in rats.

Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, Ghatei MA, Bloom SR.

Endocrinology. 2004 Jun;145(6):2687-95. Epub 2004 Mar 4.

PMID:
15001546
18.

Is glucagon-like peptide 1 an incretin hormone?

Nauck MA.

Diabetologia. 1999 Mar;42(3):373-9. Review.

PMID:
10096792
19.

Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.

Meier JJ, Gallwitz B, Schmidt WE, Nauck MA.

Eur J Pharmacol. 2002 Apr 12;440(2-3):269-79. Review.

PMID:
12007541
20.

Supplemental Content

Support Center